01Hub 1 of 6

Compound Profiles

BPC-157, TB-500, GHK-Cu, Retatrutide, and more, each opens with the Evidence Ledger.

Our thesis

One pillar per major compound. Evidence Ledger, mechanism, human data, discourse, open questions. Never a dosing prescription.

Start with the pillar

The compound profile.

Evidence Ledger for BPC-157: 50+ preclinical studies, 1 human pilot (Chang 2014, n=12), 1 active Phase trial, FDA removed from 503A list in 2023.

A 12-page PDF summary of where 10 major compounds sit, Preclinical / Human pilot / Phase trial / FDA status. Updated quarterly. Free.

By subscribing, you agree to our Privacy Policy. One calm, cited email a week. Unsubscribe anytime.